Long-term Safety Study for Ciltacabtagene Autoleucel

We are following up with patients who received cilta-cel to learn about any long-term side effects and how well the treatment works over time. This study aims to improve our understanding of the treatment's safety and effectiveness.

>2 yearsMonitoring phase (IV)No PlaceboCost ReimbursementStandard MedicinesInjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Carvykti
Carvykti is a personalized cell therapy used to treat adults with relapsed or hard-to-treat multiple myeloma.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ciltacabtagene Autoleucel
Ciltacabtagene autoleucel is a personalized cell therapy using a patient’s own modified immune cells to target and treat advanced multiple myeloma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
UZ Leuven
BE10002:Hematologie
Heverlee, Belgium
Universitair Ziekenhuis Gent
BE10004:Hematologie
Ledeberg, Belgium
Centre Hospitalier Universitaire De Lille
FR10005:Service des Maladies du Sang
Loos, France
Sponsor: Janssen - Cilag International
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.